Cancer, Depressive Disorder
Conditions
Keywords
Carcinogenicity, Case control, Bupropion
Brief summary
There is a lack of toxicology data on one bupropion metabolite, and limited literature examining bupropion use and cancer risk. This study evaluates the association between bupropion exposure and the development of cancer of the prostate, breast, lung, colon/rectum, urinary bladder, and uterus by comparing the risk of cancer in bupropion users with other antidepressant users. Because there is no evidence that bupropion is associated with any particular cancer, we have chosen the six most common cancers diagnosed in the United States to optimize statistical power/precision for cancer-site specific comparisons. Two US population-based data resources with automated claims, pharmacy, and tumor registry data are included in this study. Using a nested case-control design, this study will compare the incidence of cancer in patients exposed to bupropion with the incidence in patients exposed to other antidepressants.
Detailed description
Patients were not recruited for nor enrolled in this study. This study is a retrospective observational study. Data from medical records or insurance claims databases are anonymised and used to develop a patient cohort. All diagnoses and treatment are recorded in the course of routine medical practice.
Interventions
DRUGRegular bupropion use
Regular use of bupropion is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
DRUGRegular SSRI (Selective serotonin reuptake inhibitors) use
Regular use of SSRI is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
DRUGRegular TCA (Tricyclic antidepressants) use
Regular use of TCA is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
DRUGRegular use of any other antidepressant
Regular use of any other antidepressants is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date. An other antidepressant would be any antidepressant other than bupropion, a SSRI or a TCA.
Sponsors
GlaxoSmithKline
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\-
Exclusion criteria
* Cancers diagnosed within 12 months of initiation (i.e., new use) of antidepressant pharmacotherapy will be excluded to account for a minimum period for the development of cancer (cancer latency) and to be consistent with other studies of antidepressants and cancer. * Patients with a history of any cancer (cancer diagnosis recorded in the tumor registries anytime before the first antidepressant prescription recorded during the study period) * Any antidepressant use within 6 months of January 1, 1996
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Diagnosed With Any of the Cancers Under Investigation Who Were Regularly Exposed to the Indicated Antidepressant | January 1, 1996 - December 31, 2006 | The following are the cancers under investigation: colorectal, lung, bladder, uterus, breast, and prostate. Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Diagnosed With Lung Cancer Who Were Regularly Exposed to the Indicated Antidepressant | January 1, 1996 - December 31, 2006 | In this outcome, lung cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Lung cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. |
| Number of Participants Diagnosed With Bladder Cancer Who Were Regularly Exposed to the Indicated Antidepressant | January 1, 1996 - December 31, 2006 | In this outcome, bladder cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Bladder cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. |
| Number of Participants Diagnosed With Colorectal Cancer Who Were Regularly Exposed to the Indicated Antidepressant | January 1, 1996 - December 31, 2006 | In this outcome, colorectal cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Colorectal cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. |
| Number of Participants Diagnosed With Breast Cancer Who Were Regularly Exposed to the Indicated Antidepressant | January 1, 1996 - December 31, 2006 | In this outcome, breast cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Breast cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. |
| Number of Participants Diagnosed With Prostate Cancer Who Were Regularly Exposed to the Indicated Antidepressant | January 1, 1996 - December 31, 2006 | In this outcome, prostate cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Prostate cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. |
| Number of Participants Diagnosed With Uterine Cancer Who Were Regularly Exposed to the Indicated Antidepressant | January 1, 1996 - December 31, 2006 | In this outcome, uterine cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Uterine cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. |
Participant flow
Recruitment details
Patients were not recruited for nor enrolled in this study. This study is a retrospective observational study. Data from medical records or insurance claims databases are anonymized and used to develop a patient cohort. All diagnoses and treatment are recorded in the course of routine medical practice.
Participants by arm
| Arm | Count |
|---|---|
| New Antidepressant Exposure in Colorectal Cancer: Cases New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Colorectal Cancer: Cases | 350 |
| New Antidepressant Exposure in Colorectal Cancer: Controls New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Colorectal Cancer: Controls | 1,050 |
| New Antidepressant Exposure in Lung Cancer: Cases New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Lung Cancer: Cases | 457 |
| New Antidepressant Exposure in Lung Cancer: Controls New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Lung Cancer: Controls | 1,370 |
| New Antidepressant Exposure in Bladder Cancer: Cases New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Bladder Cancer: Cases | 294 |
| New Antidepressant Exposure in Bladder Cancer: Controls New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Bladder Cancer: Controls | 882 |
| New Antidepressant Exposure in Uterine Cancer: Cases New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Uterine Cancer: Cases | 308 |
| New Antidepressant Exposure in Uterine Cancer: Controls New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Uterine Cancer: Controls | 837 |
| New Antidepressant Exposure in Breast Cancer: Cases New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Breast Cancer: Cases | 2,842 |
| New Antidepressant Exposure in Breast Cancer: Controls New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Breast Cancer: Controls | 28,420 |
| New Antidepressant Exposure in Prostate Cancer: Cases New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Prostate Cancer: Cases | 2,215 |
| New Antidepressant Exposure in Prostate Cancer: Controls New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Prostate Cancer: Controls | 22,150 |
| Total | 61,175 |
Baseline characteristics
| Characteristic | New Antidepressant Exposure in Colorectal Cancer: Controls | New Antidepressant Exposure in Lung Cancer: Cases | New Antidepressant Exposure in Lung Cancer: Controls | New Antidepressant Exposure in Bladder Cancer: Cases | New Antidepressant Exposure in Bladder Cancer: Controls | New Antidepressant Exposure in Uterine Cancer: Cases | New Antidepressant Exposure in Uterine Cancer: Controls | New Antidepressant Exposure in Breast Cancer: Cases | New Antidepressant Exposure in Breast Cancer: Controls | New Antidepressant Exposure in Colorectal Cancer: Cases | New Antidepressant Exposure in Prostate Cancer: Cases | New Antidepressant Exposure in Prostate Cancer: Controls | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized 45-54 years | 102 Participants | 47 Participants | 140 Participants | 17 Participants | 51 Participants | 59 Participants | 172 Participants | 678 Participants | 6780 Participants | 34 Participants | 193 Participants | 1930 Participants | 10203 Participants |
| Age, Customized 55-64 years | 219 Participants | 102 Participants | 306 Participants | 63 Participants | 189 Participants | 90 Participants | 245 Participants | 849 Participants | 8490 Participants | 73 Participants | 669 Participants | 6690 Participants | 17985 Participants |
| Age, Customized 65-74 years | 357 Participants | 159 Participants | 477 Participants | 104 Participants | 312 Participants | 84 Participants | 224 Participants | 707 Participants | 7070 Participants | 119 Participants | 877 Participants | 8770 Participants | 19260 Participants |
| Age, Customized >=75 years | 372 Participants | 149 Participants | 447 Participants | 110 Participants | 330 Participants | 75 Participants | 196 Participants | 608 Participants | 6080 Participants | 124 Participants | 476 Participants | 4760 Participants | 13727 Participants |
| Number of participants diagnosed with the indicated conditions and using the indicated therapies Ever diagnosed (dx) with depression | 329 participants | 108 participants | 408 participants | 83 participants | 273 participants | 119 participants | 319 participants | 1091 participants | 10541 participants | 110 participants | 677 participants | 6700 participants | 20758 participants |
| Number of participants diagnosed with the indicated conditions and using the indicated therapies Ever dx with inflammatory bowel disease (IBD) | 9 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 1 participants | 0 participants | 0 participants | 10 participants |
| Number of participants diagnosed with the indicated conditions and using the indicated therapies Ever smokers | 643 participants | 428 participants | 772 participants | 247 participants | 573 participants | 142 participants | 389 participants | 0 participants | 0 participants | 252 participants | 0 participants | 0 participants | 3446 participants |
| Number of participants diagnosed with the indicated conditions and using the indicated therapies Exposed to multiple antidepressants | 160 participants | 62 participants | 191 participants | 44 participants | 147 participants | 53 participants | 162 participants | 564 participants | 5756 participants | 47 participants | 340 participants | 3782 participants | 11308 participants |
| Number of participants diagnosed with the indicated conditions and using the indicated therapies Unknown smoking status | 70 participants | 5 participants | 183 participants | 1 participants | 29 participants | 4 participants | 27 participants | 0 participants | 0 participants | 4 participants | 0 participants | 0 participants | 323 participants |
| Number of participants diagnosed with the indicated conditions and using the indicated therapies Users of hormone replacement therapy (HRT) | 225 participants | 0 participants | 0 participants | 0 participants | 0 participants | 153 participants | 441 participants | 1796 participants | 17184 participants | 57 participants | 0 participants | 0 participants | 19856 participants |
| Number of participants diagnosed with the indicated conditions and using the indicated therapies Users of NSAIDs | 859 participants | 370 participants | 1123 participants | 0 participants | 0 participants | 0 participants | 0 participants | 2340 participants | 23730 participants | 269 participants | 1800 participants | 17887 participants | 48378 participants |
| Number of participants diagnosed with the indicated conditions and using the indicated therapies Users of oral contraceptives (OC) | 7 participants | 0 participants | 0 participants | 0 participants | 0 participants | 8 participants | 45 participants | 236 participants | 1987 participants | 6 participants | 0 participants | 0 participants | 2289 participants |
| Sex: Female, Male Female | 378 Participants | 175 Participants | 525 Participants | 91 Participants | 273 Participants | 308 Participants | 837 Participants | 2842 Participants | 28420 Participants | 126 Participants | 0 Participants | 0 Participants | 33975 Participants |
| Sex: Female, Male Male | 672 Participants | 282 Participants | 845 Participants | 203 Participants | 609 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 224 Participants | 2215 Participants | 22150 Participants | 27200 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
Outcome results
Primary
Number of Participants Diagnosed With Any of the Cancers Under Investigation Who Were Regularly Exposed to the Indicated Antidepressant
The following are the cancers under investigation: colorectal, lung, bladder, uterus, breast, and prostate. Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.
Time frame: January 1, 1996 - December 31, 2006
Population: Participants diagnosed with colorectal, lung, bladder, uterus, breast, or prostate cancer who were new antidepressant users
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Bupropion, Regular Use | Number of Participants Diagnosed With Any of the Cancers Under Investigation Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 853 participants |
| Bupropion, Regular Use | Number of Participants Diagnosed With Any of the Cancers Under Investigation Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 6332 participants |
| All Non-bupropion Antidepressants, Regular Use | Number of Participants Diagnosed With Any of the Cancers Under Investigation Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 4561 participants |
| All Non-bupropion Antidepressants, Regular Use | Number of Participants Diagnosed With Any of the Cancers Under Investigation Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 37831 participants |
| Tricyclic Antidepressants (TCA), Regular Use | Number of Participants Diagnosed With Any of the Cancers Under Investigation Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 1963 participants |
| Tricyclic Antidepressants (TCA), Regular Use | Number of Participants Diagnosed With Any of the Cancers Under Investigation Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 16574 participants |
| Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use | Number of Participants Diagnosed With Any of the Cancers Under Investigation Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 21170 participants |
| Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use | Number of Participants Diagnosed With Any of the Cancers Under Investigation Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 2570 participants |
| Other Antidepressants, Regular Use | Number of Participants Diagnosed With Any of the Cancers Under Investigation Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 1027 participants |
| Other Antidepressants, Regular Use | Number of Participants Diagnosed With Any of the Cancers Under Investigation Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 9096 participants |
95% CI: [1, 1.2]
95% CI: [1, 1.3]
95% CI: [1, 1.2]
95% CI: [1.1, 1.3]
95% CI: [1, 1.2]
95% CI: [1.1, 1.3]
95% CI: [1.1, 1.4]
95% CI: [1, 1.3]
Secondary
Number of Participants Diagnosed With Bladder Cancer Who Were Regularly Exposed to the Indicated Antidepressant
In this outcome, bladder cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Bladder cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.
Time frame: January 1, 1996 - December 31, 2006
Population: Participants diagnosed with bladder cancer who were new antidepressant users.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Bupropion, Regular Use | Number of Participants Diagnosed With Bladder Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 48 participants |
| Bupropion, Regular Use | Number of Participants Diagnosed With Bladder Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 77 participants |
| All Non-bupropion Antidepressants, Regular Use | Number of Participants Diagnosed With Bladder Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 191 participants |
| All Non-bupropion Antidepressants, Regular Use | Number of Participants Diagnosed With Bladder Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 662 participants |
| Tricyclic Antidepressants (TCA), Regular Use | Number of Participants Diagnosed With Bladder Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 88 participants |
| Tricyclic Antidepressants (TCA), Regular Use | Number of Participants Diagnosed With Bladder Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 297 participants |
| Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use | Number of Participants Diagnosed With Bladder Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 351 participants |
| Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use | Number of Participants Diagnosed With Bladder Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 103 participants |
| Other Antidepressants, Regular Use | Number of Participants Diagnosed With Bladder Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 40 participants |
| Other Antidepressants, Regular Use | Number of Participants Diagnosed With Bladder Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 159 participants |
95% CI: [1.7, 4.1]
95% CI: [1.3, 3.4]
95% CI: [1.4, 3.6]
95% CI: [1.1, 3]
95% CI: [1.5, 3.7]
95% CI: [1.1, 3]
95% CI: [1.5, 4.5]
95% CI: [1.3, 3.9]
Secondary
Number of Participants Diagnosed With Breast Cancer Who Were Regularly Exposed to the Indicated Antidepressant
In this outcome, breast cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Breast cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.
Time frame: January 1, 1996 - December 31, 2006
Population: Participants diagnosed with breast cancer who were new antidepressant users.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Bupropion, Regular Use | Number of Participants Diagnosed With Breast Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 2966 participants |
| Bupropion, Regular Use | Number of Participants Diagnosed With Breast Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 302 participants |
| All Non-bupropion Antidepressants, Regular Use | Number of Participants Diagnosed With Breast Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 2173 participants |
| All Non-bupropion Antidepressants, Regular Use | Number of Participants Diagnosed With Breast Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 21188 participants |
| Tricyclic Antidepressants (TCA), Regular Use | Number of Participants Diagnosed With Breast Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 9338 participants |
| Tricyclic Antidepressants (TCA), Regular Use | Number of Participants Diagnosed With Breast Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 941 participants |
| Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use | Number of Participants Diagnosed With Breast Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 1265 participants |
| Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use | Number of Participants Diagnosed With Breast Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 12189 participants |
| Other Antidepressants, Regular Use | Number of Participants Diagnosed With Breast Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 497 participants |
| Other Antidepressants, Regular Use | Number of Participants Diagnosed With Breast Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 5141 participants |
95% CI: [0.8, 1.1]
95% CI: [0.8, 1.1]
95% CI: [0.9, 1.2]
95% CI: [0.8, 1.1]
95% CI: [0.8, 1.1]
95% CI: [0.8, 1.1]
95% CI: [0.9, 1.3]
95% CI: [0.9, 1.2]
Secondary
Number of Participants Diagnosed With Colorectal Cancer Who Were Regularly Exposed to the Indicated Antidepressant
In this outcome, colorectal cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Colorectal cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.
Time frame: January 1, 1996 - December 31, 2006
Population: Participants diagnosed with colorectal cancer who were new antidepressant users.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Bupropion, Regular Use | Number of Participants Diagnosed With Colorectal Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 37 participants |
| Bupropion, Regular Use | Number of Participants Diagnosed With Colorectal Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 89 participants |
| All Non-bupropion Antidepressants, Regular Use | Number of Participants Diagnosed With Colorectal Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 234 participants |
| All Non-bupropion Antidepressants, Regular Use | Number of Participants Diagnosed With Colorectal Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 739 participants |
| Tricyclic Antidepressants (TCA), Regular Use | Number of Participants Diagnosed With Colorectal Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 111 participants |
| Tricyclic Antidepressants (TCA), Regular Use | Number of Participants Diagnosed With Colorectal Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 321 participants |
| Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use | Number of Participants Diagnosed With Colorectal Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 411 participants |
| Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use | Number of Participants Diagnosed With Colorectal Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 134 participants |
| Other Antidepressants, Regular Use | Number of Participants Diagnosed With Colorectal Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 35 participants |
| Other Antidepressants, Regular Use | Number of Participants Diagnosed With Colorectal Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 166 participants |
95% CI: [0.9, 2.2]
95% CI: [0.8, 2]
95% CI: [0.8, 2]
95% CI: [0.7, 1.9]
95% CI: [0.8, 2.1]
95% CI: [0.7, 1.9]
95% CI: [1.2, 3.9]
95% CI: [1.1, 3.6]
Secondary
Number of Participants Diagnosed With Lung Cancer Who Were Regularly Exposed to the Indicated Antidepressant
In this outcome, lung cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Lung cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.
Time frame: January 1, 1996 - December 31, 2006
Population: Participants diagnosed with lung cancer who were new antidepressant users.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Bupropion, Regular Use | Number of Participants Diagnosed With Lung Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 115 participants |
| Bupropion, Regular Use | Number of Participants Diagnosed With Lung Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 125 participants |
| All Non-bupropion Antidepressants, Regular Use | Number of Participants Diagnosed With Lung Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 250 participants |
| All Non-bupropion Antidepressants, Regular Use | Number of Participants Diagnosed With Lung Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 922 participants |
| Tricyclic Antidepressants (TCA), Regular Use | Number of Participants Diagnosed With Lung Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 109 participants |
| Tricyclic Antidepressants (TCA), Regular Use | Number of Participants Diagnosed With Lung Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 389 participants |
| Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use | Number of Participants Diagnosed With Lung Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 532 participants |
| Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use | Number of Participants Diagnosed With Lung Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 138 participants |
| Other Antidepressants, Regular Use | Number of Participants Diagnosed With Lung Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 47 participants |
| Other Antidepressants, Regular Use | Number of Participants Diagnosed With Lung Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 186 participants |
95% CI: [3.2, 6.3]
95% CI: [2, 4.4]
95% CI: [2.8, 5.8]
95% CI: [1.9, 4.5]
95% CI: [3.1, 6.3]
95% CI: [1.9, 4.5]
95% CI: [2.8, 7.2]
95% CI: [2.1, 5.9]
Secondary
Number of Participants Diagnosed With Prostate Cancer Who Were Regularly Exposed to the Indicated Antidepressant
In this outcome, prostate cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Prostate cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.
Time frame: January 1, 1996 - December 31, 2006
Population: Participants diagnosed with prostate cancer who were new antidepressant users.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Bupropion, Regular Use | Number of Participants Diagnosed With Prostate Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 3224 participants |
| Bupropion, Regular Use | Number of Participants Diagnosed With Prostate Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 326 participants |
| All Non-bupropion Antidepressants, Regular Use | Number of Participants Diagnosed With Prostate Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 15562 participants |
| All Non-bupropion Antidepressants, Regular Use | Number of Participants Diagnosed With Prostate Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 1480 participants |
| Tricyclic Antidepressants (TCA), Regular Use | Number of Participants Diagnosed With Prostate Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 6836 participants |
| Tricyclic Antidepressants (TCA), Regular Use | Number of Participants Diagnosed With Prostate Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 600 participants |
| Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use | Number of Participants Diagnosed With Prostate Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 806 participants |
| Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use | Number of Participants Diagnosed With Prostate Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 8306 participants |
| Other Antidepressants, Regular Use | Number of Participants Diagnosed With Prostate Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 3726 participants |
| Other Antidepressants, Regular Use | Number of Participants Diagnosed With Prostate Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 363 participants |
95% CI: [1, 1.3]
95% CI: [1, 1.3]
95% CI: [0.9, 1.2]
95% CI: [1, 1.4]
95% CI: [1, 1.4]
95% CI: [0.9, 1.2]
95% CI: [0.9, 1.3]
95% CI: [0.8, 1.2]
Secondary
Number of Participants Diagnosed With Uterine Cancer Who Were Regularly Exposed to the Indicated Antidepressant
In this outcome, uterine cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Uterine cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.
Time frame: January 1, 1996 - December 31, 2006
Population: Participants diagnosed with uterine cancer who were new antidepressant users.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Bupropion, Regular Use | Number of Participants Diagnosed With Uterine Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 25 participants |
| Bupropion, Regular Use | Number of Participants Diagnosed With Uterine Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 91 participants |
| All Non-bupropion Antidepressants, Regular Use | Number of Participants Diagnosed With Uterine Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 233 participants |
| All Non-bupropion Antidepressants, Regular Use | Number of Participants Diagnosed With Uterine Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 633 participants |
| Tricyclic Antidepressants (TCA), Regular Use | Number of Participants Diagnosed With Uterine Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 114 participants |
| Tricyclic Antidepressants (TCA), Regular Use | Number of Participants Diagnosed With Uterine Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 257 participants |
| Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use | Number of Participants Diagnosed With Uterine Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 360 participants |
| Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use | Number of Participants Diagnosed With Uterine Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 124 participants |
| Other Antidepressants, Regular Use | Number of Participants Diagnosed With Uterine Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Cases | 45 participants |
| Other Antidepressants, Regular Use | Number of Participants Diagnosed With Uterine Cancer Who Were Regularly Exposed to the Indicated Antidepressant | Controls | 165 participants |
95% CI: [0.5, 1.3]
95% CI: [0.4, 1.2]
95% CI: [0.4, 1.1]
95% CI: [0.3, 1]
95% CI: [0.5, 1.4]
95% CI: [0.4, 1.4]
95% CI: [0.6, 2]
95% CI: [0.6, 1.9]